These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://philippkty778081.pages10.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-74445386